George Bickerstaff is currently co-founder and Managing Director of M.M. Dillon & Co., a leading healthcare and technology boutique investment bank.
Prior to co-founding M.M. Dillon, he had a successful career as a corporate executive in the technology and healthcare industries, most recently as the Chief Financial Officer of Novartis Pharma AG.
He currently serves on the Boards of Innoviva and CareDx, among others, and previously served on the Boards of Axovant Sciences, Inovio and ARIAD, which was acquired by Takeda for $5.2 billion in 2017.
Mr. Bickerstaff brings financial and operation experience in the healthcare, pharmaceutical and information technology industries, along with expertise in accounting and requlatory matters and insights into the views of shareholders, investors, analysts, and others in the financial community.
George’s philanthropic interests are in global healthcare and child protection. He is currently the Chairman of the Board of Trustees of the International Vaccine Institute and Vice Chairman of the Board of the International Centre for Missing and Exploited Children.
George has degrees in engineering and business administration. Investor, executive and board member with broad international experiences in healthcare, pharmaceuticals, biotechnology, information technology, and financial services. Member of multiple public, private and global foundation boards. Degrees in engineering and business.